NCT04916132Recruiting
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors
Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 1 Jun 2021
- Start date
- 10 Aug 2021
- Primary completion date
- 31 Dec 2043
- Lead sponsor
- Herlev Hospital
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT04916132
What you commit to
- Study type: Observational
- Planned participants: 300
- From 10 Aug 2021 to the primary completion date, 31 Dec 2043
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy
- Kidney transplant recipient
- Previous medical kidney biopsy
- Treatment with Marcoumar (all other anticoagulants are accepted)
- Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy
- If a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.
Other illness
- High thromboembolic risk combined with held in anticoagulation therapy according to the report "Perioperative regulation of antithrombotic treatment" (PRAB) (22)
- mechanical heart valve
- atrial fibrillation AND CHA2DS2-VASc\> 5 and/or stroke within the last three months
- recurrent venous thromboembolism OR venous thromboembolism within the last three months
- less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))
- less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))
- less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)
- less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)
- less than 3 months after revascularization in individuals with stable CAD (PCI with DES)
- less than 3 months after stroke, or Transient Ischemic Attack (TIA)
Lab values
- Factors that increases the risk of complications due to kidney biopsy:
- Hemoglobin \< 6 mmol/L
- INR \>1,4 at the time for biopsy
- Platelet count \< 100 x 109/l
- Uncontrolled high blood pressure (defined as systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg)
- Only one functioning kidney
- Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy
- Multiple bilateral kidney cysts
- Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy
- Unwilling to receive blood transfusion
- Unable to lie flat in bed six hours after biopsy
- Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines
Other
- Unable to understand written and oral information
- Women who are pregnant or planning to become pregnant before the kidney biopsy is performed
Who the study is looking for
- Age ≥ 18 years
- Written informed consent
- Diagnosis with T2DM according to the American diabetes Association (20)
- eGFR \>30 mL/min/1.73 m2 (maximum six months old)
- urine-albumin/creatinine-ratio (uACR) \> 700 mg/g or 24 hours urine albumin \>700 mg on more than one measurement
Age in the registry: 18 years to 120 years · Sex: All
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg Universitetshospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
| Steno Diabetes Center Copenhagen Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
| Regionshospitalet Gødstrup Coordinator of this site? Confirm its status | Gødstrup | Denmark | Recruiting |
| Herlev Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Recruiting |
| Kristine D Schandorff Coordinator of this site? Confirm its status | Hillerød | Denmark | Recruiting |
| Holbæk Hospital Coordinator of this site? Confirm its status | Holbæk | Denmark | Recruiting |
| Sjællands Universitetshospital Køge Coordinator of this site? Confirm its status | Køge | Denmark | Recruiting |
| Nykøbing Falster Sygehus Coordinator of this site? Confirm its status | Nykøbing Falster | Denmark | Recruiting |
| Odense Universitetshospital Coordinator of this site? Confirm its status | Odense | Denmark | Recruiting |
| Sjællands Universitetshospital_Roskilde Coordinator of this site? Confirm its status | Roskilde | Denmark | Recruiting |
| Aarhus Universitetshospital, Skejby Coordinator of this site? Confirm its status | Skejby | Denmark | Recruiting |
| Slagelse Sygehus Coordinator of this site? Confirm its status | Slagelse | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.